title: Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone.
abstract: OBJECTIVE
  To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD) among patients with psychosis of Alzheimer's disease (AD).
  
  
  METHODS
  Post hoc exploratory analysis of data on 479 nursing-home patients with psychosis of AD from three 12-week, double-blind, placebo-controlled clinical trials. Criteria for psychosis of AD were a diagnosis of AD or mixed dementia and a rating of >/= 2 on any delusion or hallucination item of the Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) rating scale when entering the trial. Mean changes from baseline to endpoint were examined for items on the Cohen-Mansfield Agitation Inventory (CMAI) and BEHAVE- AD.
  
  
  RESULTS
  On the CMAI, risperidone was significantly more effective than placebo in treating cursing or verbal aggression (p = 0.004), hitting (p < 0.001), performing repetitious mannerisms (p < 0.001), pacing, aimless wandering (p = 0.017), hoarding things (p = 0.02), hiding things (p = 0.02) and repetitive sentences or questions (p = 0.025). On the BEHAVE-AD, risperidone was significantly more effective than placebo in treating physical threats and/or violence (p = 0.001), agitation (other) (p = 0.001) and verbal outbursts (p = 0.026). Although analysis on individual hallucination and delusional items did not demonstrate specific responses, analyses of a composite of delusional items revealed significant drug-placebo differences.
  
  
  CONCLUSIONS
  These data indicate that risperidone is effective in treating a variety of symptoms associated with psychosis of AD.
authors.affiliation: Bar Ilan University, Ramat Gan, Israel.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Rabinowitz
authors.forename: Ira
authors.initials: I
authors.lastname: Katz
authors.forename: Peter Paul
authors.initials: PP
authors.lastname: De Deyn
authors.forename: Andrew
authors.initials: A
authors.lastname: Greenspan
authors.forename: Henry
authors.initials: H
authors.lastname: Brodaty
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000453:epidemiology*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011595:Psychomotor Agitation / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000453:epidemiology*; D018967:Risperidone / Q000627:therapeutic use*; D011795:Surveys and Questionnaires
chemical_list: D014150:Antipsychotic Agents; D018967:Risperidone